Neurologic Complications of Systemic Anticancer Therapy

Area of Science:

• Neuro-oncology
• Cancer Therapeutics
• Neurology

Background:

• Systemic cancer therapies, including targeted therapy and immunotherapy, are increasingly associated with neurologic complications.
• The rising number of long-term cancer survivors contributes to a growing incidence of treatment-related nervous system adverse effects.
• Accurate identification of these complications is vital to prevent misdiagnosis of cancer recurrence or paraneoplastic syndromes.

Purpose of the Study:

• To review the spectrum of neurologic complications arising from systemic cancer treatments.
• To highlight the importance of recognizing treatment-related neurotoxicity.
• To discuss strategies for identifying patient-specific risk factors and developing preventive/therapeutic approaches.

Main Methods:

• Review of current literature on cancer therapy-induced neurologic complications.
• Analysis of emerging trends in targeted therapy and immunotherapy adverse effects.
• Discussion of diagnostic challenges and management strategies.

Main Results:

• Neurologic complications can manifest in the central nervous system (CNS), peripheral nervous system (PNS), or both.
• Novel cancer agents pose unique neurotoxic risks.
• Distinguishing treatment effects from disease progression or paraneoplastic phenomena is a key clinical challenge.

Conclusions:

• Neurologic complications are an increasingly significant concern in cancer care.
• Further research is needed to elucidate patient-specific risk factors for neurotoxicity.
• Developing targeted preventive and therapeutic strategies is essential for improving outcomes in cancer survivors.